176 related articles for article (PubMed ID: 25742476)
1. Prognostic and predictive value of immunological parameters for chemoradioimmunotherapy in patients with pancreatic adenocarcinoma.
Karakhanova S; Ryschich E; Mosl B; Harig S; Jäger D; Schmidt J; Hartwig W; Werner J; Bazhin AV
Br J Cancer; 2015 Mar; 112(6):1027-36. PubMed ID: 25742476
[TBL] [Abstract][Full Text] [Related]
2. Impact of interferon-alpha in combined chemoradioimmunotherapy for pancreatic adenocarcinoma (CapRI): first data from the immunomonitoring.
Schmidt J; Jäger D; Hoffmann K; Büchler MW; Märten A
J Immunother; 2007 Jan; 30(1):108-15. PubMed ID: 17198089
[TBL] [Abstract][Full Text] [Related]
3. Effect of pemetrexed on innate immune killer cells and adaptive immune T cells in subjects with adenocarcinoma of the pancreas.
Davis M; Conlon K; Bohac GC; Barcenas J; Leslie W; Watkins L; Lamzabi I; Deng Y; Li Y; Plate JM
J Immunother; 2012 Oct; 35(8):629-40. PubMed ID: 22996369
[TBL] [Abstract][Full Text] [Related]
4. Impact of surgery and chemotherapy on cellular immunity in pancreatic carcinoma patients in view of an integration of standard cancer treatment with immunotherapy.
Bellone G; Novarino A; Vizio B; Brondino G; Addeo A; Prati A; Giacobino A; Campra D; Fronda GR; Ciuffreda L
Int J Oncol; 2009 Jun; 34(6):1701-15. PubMed ID: 19424589
[TBL] [Abstract][Full Text] [Related]
5. Expansion of Tumor-reactive T Cells From Patients With Pancreatic Cancer.
Meng Q; Liu Z; Rangelova E; Poiret T; Ambati A; Rane L; Xie S; Verbeke C; Dodoo E; Del Chiaro M; Löhr M; Segersvärd R; Maeurer MJ
J Immunother; 2016; 39(2):81-9. PubMed ID: 26849077
[TBL] [Abstract][Full Text] [Related]
6. 5-Fluorouracil and interferon-α immunochemotherapy enhances immunogenicity of murine pancreatic cancer through upregulation of NKG2D ligands and MHC class I.
Khallouf H; Märten A; Serba S; Teichgräber V; Büchler MW; Jäger D; Schmidt J
J Immunother; 2012 Apr; 35(3):245-53. PubMed ID: 22421942
[TBL] [Abstract][Full Text] [Related]
7. Influence of interferon-alpha combined with chemo (radio) therapy on immunological parameters in pancreatic adenocarcinoma.
Karakhanova S; Mosl B; Harig S; von Ahn K; Fritz J; Schmidt J; Jäger D; Werner J; Bazhin AV
Int J Mol Sci; 2014 Mar; 15(3):4104-25. PubMed ID: 24608924
[TBL] [Abstract][Full Text] [Related]
8. Open-label, multicenter, randomized phase III trial of adjuvant chemoradiation plus interferon Alfa-2b versus fluorouracil and folinic acid for patients with resected pancreatic adenocarcinoma.
Schmidt J; Abel U; Debus J; Harig S; Hoffmann K; Herrmann T; Bartsch D; Klein J; Mansmann U; Jäger D; Capussotti L; Kunz R; Büchler MW
J Clin Oncol; 2012 Nov; 30(33):4077-83. PubMed ID: 23008325
[TBL] [Abstract][Full Text] [Related]
9. Changes in immunological parameters during interleukin 2 and interferon 2 alpha treatment of recurrent renal cell carcinoma and malignant melanoma.
Maxwell W; McDevitt J; Reid I; Sharpe I; Feighery C; Tanner WA; Emmons R; Monson JR
Eur J Surg Oncol; 1993 Jun; 19(3):265-72. PubMed ID: 8314385
[TBL] [Abstract][Full Text] [Related]
10. Improved Natural Killer cell activity and retained anti-tumor CD8(+) T cell responses contribute to the induction of a pathological complete response in HER2-positive breast cancer patients undergoing neoadjuvant chemotherapy.
Muraro E; Comaro E; Talamini R; Turchet E; Miolo G; Scalone S; Militello L; Lombardi D; Spazzapan S; Perin T; Massarut S; Crivellari D; Dolcetti R; Martorelli D
J Transl Med; 2015 Jun; 13():204. PubMed ID: 26116238
[TBL] [Abstract][Full Text] [Related]
11. The Prognostic Impact of NK/NKT Cell Density in Periampullary Adenocarcinoma Differs by Morphological Type and Adjuvant Treatment.
Lundgren S; Warfvinge CF; Elebro J; Heby M; Nodin B; Krzyzanowska A; Bjartell A; Leandersson K; Eberhard J; Jirström K
PLoS One; 2016; 11(6):e0156497. PubMed ID: 27275582
[TBL] [Abstract][Full Text] [Related]
12. Predictive value of CD8highCD57+ lymphocyte subset in interferon therapy of patients with renal cell carcinoma.
Characiejus D; Pasukoniene V; Kazlauskaite N; Valuckas KP; Petraitis T; Mauricas M; Den Otter W
Anticancer Res; 2002; 22(6B):3679-83. PubMed ID: 12552976
[TBL] [Abstract][Full Text] [Related]
13. Chronic hepatitis C in the advanced adult and elderly subjects.
Gattoni A; Parlato A; Vangieri B; Bresciani M; Petraccaro M
Minerva Gastroenterol Dietol; 2009 Jun; 55(2):145-57. PubMed ID: 19305374
[TBL] [Abstract][Full Text] [Related]
14. Regulatory T cells, interleukin (IL)-6, IL-8, vascular endothelial growth factor (VEGF), CXCL10, CXCL11, epidermal growth factor (EGF) and hepatocyte growth factor (HGF) as surrogate markers of host immunity in patients with renal cell carcinoma.
Polimeno M; Napolitano M; Costantini S; Portella L; Esposito A; Capone F; Guerriero E; Trotta A; Zanotta S; Pucci L; Longo N; Perdonà S; Pignata S; Castello G; Scala S
BJU Int; 2013 Sep; 112(5):686-96. PubMed ID: 23495770
[TBL] [Abstract][Full Text] [Related]
15. Prognostic impact of immune response in resectable colorectal liver metastases treated by surgery alone or surgery with perioperative FOLFOX in the randomised EORTC study 40983.
Tanis E; Julié C; Emile JF; Mauer M; Nordlinger B; Aust D; Roth A; Lutz MP; Gruenberger T; Wrba F; Sorbye H; Bechstein W; Schlag P; Fisseler A; Ruers T
Eur J Cancer; 2015 Nov; 51(17):2708-17. PubMed ID: 26342674
[TBL] [Abstract][Full Text] [Related]
16. Low-dose interleukin-2 administered pre-operatively to patients with gastric cancer activates peripheral and peritumoral lymphocytes but does not affect prognosis.
Cesana GC; Romano F; Piacentini G; Scotti M; Brenna A; Bovo G; Vaghi M; Aletti G; Caprotti R; Kaufman H; Uggeri F
Ann Surg Oncol; 2007 Apr; 14(4):1295-304. PubMed ID: 17225981
[TBL] [Abstract][Full Text] [Related]
17. Tumor-infiltrating lymphocytes contain higher numbers of type 1 cytokine expressors and DR+ T cells compared with lymphocytes from tumor draining lymph nodes and peripheral blood in patients with cancer of the uterine cervix.
Santin AD; Ravaggi A; Bellone S; Pecorelli S; Cannon M; Parham GP; Hermonat PL
Gynecol Oncol; 2001 Jun; 81(3):424-32. PubMed ID: 11371133
[TBL] [Abstract][Full Text] [Related]
18. Phase III trial of postoperative cisplatin, interferon alpha-2b, and 5-FU combined with external radiation treatment versus 5-FU alone for patients with resected pancreatic adenocarcinoma -- CapRI: study protocol [ISRCTN62866759].
Knaebel HP; Märten A; Schmidt J; Hoffmann K; Seiler C; Lindel K; Schmitz-Winnenthal H; Fritz S; Herrmann T; Goldschmidt H; Krempien R; Mansmann U; Debus J; Diehl V; Büchler MW
BMC Cancer; 2005 Apr; 5():37. PubMed ID: 15826316
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical characterisation of immunological changes at the tumour site after chemo-immunotherapy with doxorubicin, interleukin-2 and interferon-gamma.
Lumsden AJ; Codde JP; Van der Meide PH; Gray BN
Anticancer Res; 1996; 16(3A):1145-54. PubMed ID: 8702226
[TBL] [Abstract][Full Text] [Related]
20. CD69 on CD56+ NK cells and response to chemoimmunotherapy in metastatic melanoma.
Konjević G; Jović V; Vuletić A; Radulović S; Jelić S; Spuzić I
Eur J Clin Invest; 2007 Nov; 37(11):887-96. PubMed ID: 17973783
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
